UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $5.25 Million Investment in Astrana Health, Inc. (NASDAQ:ASTH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 90,520 shares of the company’s stock, valued at approximately $5,245,000.

A number of other large investors have also recently made changes to their positions in the stock. Royce & Associates LP purchased a new position in Astrana Health during the 3rd quarter worth $6,661,000. Amalgamated Bank bought a new position in shares of Astrana Health during the 3rd quarter worth $713,000. Principal Financial Group Inc. purchased a new position in shares of Astrana Health during the third quarter valued at $13,383,000. Diamond Hill Capital Management Inc. purchased a new stake in Astrana Health in the third quarter worth about $8,245,000. Finally, Summit Global Investments bought a new position in Astrana Health during the 3rd quarter worth about $753,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Price Performance

Shares of ASTH opened at $38.50 on Thursday. The company has a 50 day moving average of $50.37 and a two-hundred day moving average of $48.11. The company has a market cap of $2.17 billion, a price-to-earnings ratio of 29.62, a price-to-earnings-growth ratio of 1.94 and a beta of 1.14. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a twelve month low of $32.66 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. During the same period in the previous year, the business earned $0.47 EPS. As a group, analysts predict that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ASTH. Robert W. Baird boosted their price target on shares of Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. KeyCorp began coverage on shares of Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen initiated coverage on Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. Finally, BTIG Research lifted their price target on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.